Our Specialization
AAVnerGene is a leading biotech company specializing in advanced gene therapy technologies using the AAV platform. Found in Rockville, Maryland, our state-of-the-art facility spans over 10,000 square feet, is dedicated to developing innovative gene therapy solutions. With 20+ years of AAV gene therapy expertise, our leadership team has contributed to a multitude of groundbreaking publications and patented technologies. The company’s mission is to AAV transduction efficiency, safety, and scalability while significantly reducing manufacturing costs, ultimately making AAV gene therapy more effective, accessible, and affordable for patients.
With more than 20 years of experience in AAV gene therapy development, AAVnerGene can provide AAV services, covering AAV vector design, AAV packaging, AAV characterization, AAV library production and AAV capsid evolution to accelerate therapeutic discovery and preclinical validation. We also provide comprehensive AAV QC analysis services(such as AAV capsid structure and AAV purity, AAV full-to-empty particle ratio, AAV physical titer and AAV infectious titer, AAV genome integrity, AAV neutralizing antibody (NAb) profiling, and AAV biosafety assessment) and high quality AAV products(including
AAV plasmids, viral vectors, reference standards, and AAV capsid libraries). AAVnerGene has established three core technology platforms that serve as the foundation for its gene therapy innovation, including AAVone single-plasmid AAV production system, ATHENA AAV capsid engineering platform, and AAV-Q AAV potency and rcAAV assays.
AAVone Single-Plasmid Production System
AAVone Single-Plasmid Production System – an advanced AAV manufacturing platform designed to streamline vector production, improve yield and purity, and reduce cost and labor. In AAVone, all essential components—including Ad helper genes (E2A, E4orf6, VA RNA), AAV Rep and Cap genes, and the vector genome—are assembled into a single plasmid, enabling one-step transfection. This innovation delivers 2–4× higher productivity than the traditional triple-plasmid method, achieving AAV9 yields up to 5.0 × 10¹⁵ VG/L in HEK293 cells, with excellent reproducibility and GMP scalability.
ATHENA Capsid Engineering Platform
ATHENA Capsid Engineering Platform – a multi-dimensional system integrating ATHENA-I, ATHENA-II, and ATHENA-III sub-platforms with artificial intelligence (AI) to accelerate AAV capsid discovery and optimization. Through high-throughput screening and AI-guided analysis, ATHENA enables the efficient identification and evolution of AAV variants with superior tissue tropism and transduction profiles. Using this platform, AAVnerGene has discovered capsids demonstrating robust transduction in the brain, retina, kidney, and lung across both mouse and non-human primate (NHP) models, the multi-organ targeting needs of this proposal.
AAV-Q Platform for AAV Potency (TCID50) and rcAAV Assay
The AAV-Q Platform is AAVnerGene’s comprehensive analytical system designed to ensure high-quality, safe, and consistent AAV vector production. Among its core capabilities, AAV-Q provides precise assessment of infectious titer (TCID₅₀) and replication-competent AAV (rcAAV) contamination.
📌 LinkedIn: https://lnkd.in/g8qqvtSZ
☎️ Phone: +1 3016057502
📭 Email: customer@aavnergene.com
📍 9620 Medical Center Dr, Suite 100，Rockville, MD 20850